Protas announces new agreement to streamline clinical trials with GSK
GSK has signed a new three-year agreement with Protas that aims to streamline trials across several core therapeutic areas. Protas will provide a variety of…
The latest in smarter trials
As a not-for-profit, our mission is to enable whole-system change in clinical trials. This means sharing our approach and knowledge with our community. From news about Protas, our partnerships and trials, to advice and guidance, discover more about our world.
Participant centred trials: reducing burden as a moral obligation
Emma Law makes the case for the moral contract that should sit at the heart of every clinical trial.
Annalisa Jenkins awarded OBE
The award was given in recognition of outstanding services to life sciences.
What’s on your 2026 wish list?
Protas senior team share what they want to see change in clinical trials this year.
Enabling community research through policy and practice change
Watch Prof Sir Martin Landray at Milken Institute’s Future of Health Summit 2025.
Meet the team: Monique Morar, Trial Manager
Monique Morar shares her transition into trial management and what her background in nursing brings.
Melanie Ivarsson joins Protas Board of Directors
Melanie Ivarsson OBE brings over 25 years of leadership in life sciences and clinical development to Protas.
Protas continues global expansion of Cantata
Cantata platform is now being used in 12 countries, supporting 2 trials simultaneously.
Protas welcomes Annalisa Jenkins to Board of Directors
Dr Annalisa Jenkins brings over 25 years of life sciences experience to Protas.
Chair of the Board recognised in 2025 Royal Society Awards
Professor Sir Rory Collins was awarded the Buchanan Medal for distinguished contributions to biomedical sciences.
Big clinical trials are broken – together we can fix the system
Jen Dumbleton explores novel ways to improve the success rate of large RCTs.
Learnings about clinical trial design from COVID-19
Protas colleagues have published a new article exploring what COVID-19 taught us about improving clinical trial design.